Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has infused $46m into four early-stage research companies working on Conditionally Active Biologics (CABs), immuno-oncology, neurodegenerative technologies and gene therapy.
Subscribe to our email newsletter
The first four investments under the company’s new focus have gone to BioAlta, NextCure, Cortexyme and 4D Molecular Therapeutcs.
The move will allow the recipients to fully explore their platforms in order to advance new therapeutic pathways.
BioAtla and Pfizer will each have a license to the each others respective technology to develop and commercialize various drug-conjugated conditionally-active antibodies.
Pfizer will have an exclusive option to develop and commercialize BioAtla CAB antibodies that target CTLA4, an immuno-oncology target in humans.
NextCure is engaged in the discovery and development of novel immuno-oncology therapeutic products.
Cortexyme is developing novel treatments that intend to change the course of neurodegenerative diseases.
4D Molecular Therapeutics is working to design, develop and commercialize potentially transformative gene therapy products for serious unmet medical needs.
Pfizer Worldwide Research and Development president Mikael Dolsten said: "There is exciting scientific discovery happening both within Pfizer and beyond our walls, and we look forward to continuing to explore opportunities to bring our resources to emerging companies investigating in areas where we feel we could make a difference for patients."
Separately, Pfizer has entered into translational research collaboration with Adaptive Biotechnologies to help advance novel immuno-oncology solutions.